Patients Drop MS Drug, Face Relapse Risk MedPage Today Of the nine patients who switched away from natalizumab, seven chose injectable drugs including interferon-beta products, glatiramer acetate (Copaxone), or rituximab (Rituxan). Two chose the oral drug fingolimod (Gilenya). Cheng said patients underwent ... |
